CBD (Group 5) for Cannabis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Centre de recherche du Centre Hospitalier Universitaire de Montréal, Montréal, CanadaCannabisCannabis 20 mg, - Drug
Eligibility
21 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trialexamines the effects of 4 different doses of CBD on the body, to see if they produce a pleasant effect that can't be detected with current research tools.

Eligible Conditions
  • Cannabis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 9 Secondary · Reporting Duration: Baseline and after ingestion at (60 minutes, 120 minutes, 210 minutes, 300 minutes, 360 minutes)

Baseline and after ingestion at ( 60 minutes, 120 minutes, 210 minutes, 300 minutes, 360 minutes)
Change in plasma concentration of 7-Carboxy-Cannabidiol
Change in plasma concentration of 7-Hydroxy-cannabidiol
Change in plasma concentration of Anandamide
Change in plasma concentration of CBD
Baseline and after ingestion at (120 minutes, 300 minutes)
Change in Affect
Change in Anxiety Symptoms
Change in dissociation
Baseline and after ingestion at (60 minutes, 120 minutes, 210 minutes, 300 minutes, 360 minutes)
Change in Safety
Therapeutic procedure
Baseline and after ingestion at 210 minutes
Change on cognition
End of the visit, approximatively 360 minutes after ingestion
Visit Intoxication Assessment
T5 (360 minutes after ingestion)
Cannabis-Specific Subjective Effects
Drug Effects associated with cannabis ingestion
Pleasant drug effect

Trial Safety

Safety Progress

1 of 3

Trial Design

10 Treatment Groups

CBD (Group 5)
1 of 10
CBD (Group 4)
1 of 10
0 mg CBD, ingested placebo
1 of 10
20 mg CBD, ingested CBD
1 of 10
50 mg CBD, ingested CBD
1 of 10
100 mg CBD, ingested CBD
1 of 10
200 mg CBD, ingested CBD
1 of 10
CBD (Group 3)
1 of 10
CBD (Group 1)
1 of 10
CBD (Group 2)
1 of 10

Experimental Treatment

70 Total Participants · 10 Treatment Groups

Primary Treatment: CBD (Group 5) · Has Placebo Group · Phase 1 & 2

CBD (Group 5)
Drug
Experimental Group · 1 Intervention: Cannabis, placebo · Intervention Types: Drug
CBD (Group 4)
Drug
Experimental Group · 1 Intervention: Cannabis, placebo · Intervention Types: Drug
0 mg CBD, ingested placeboExperimental Group · 5 Interventions: cannabis 0 mg, placebo, Cannabis 20 mg,, Cannabis 50 mg, Cannabis 100 mg, Cannabis 200 mg · Intervention Types: Drug, Drug, Drug, Drug, Drug
20 mg CBD, ingested CBDExperimental Group · 5 Interventions: cannabis 0 mg, placebo, Cannabis 20 mg,, Cannabis 50 mg, Cannabis 100 mg, Cannabis 200 mg · Intervention Types: Drug, Drug, Drug, Drug, Drug
50 mg CBD, ingested CBDExperimental Group · 5 Interventions: cannabis 0 mg, placebo, Cannabis 20 mg,, Cannabis 50 mg, Cannabis 100 mg, Cannabis 200 mg · Intervention Types: Drug, Drug, Drug, Drug, Drug
100 mg CBD, ingested CBDExperimental Group · 5 Interventions: cannabis 0 mg, placebo, Cannabis 20 mg,, Cannabis 50 mg, Cannabis 100 mg, Cannabis 200 mg · Intervention Types: Drug, Drug, Drug, Drug, Drug
200 mg CBD, ingested CBDExperimental Group · 5 Interventions: cannabis 0 mg, placebo, Cannabis 20 mg,, Cannabis 50 mg, Cannabis 100 mg, Cannabis 200 mg · Intervention Types: Drug, Drug, Drug, Drug, Drug
CBD (Group 3)
Drug
Experimental Group · 1 Intervention: Cannabis, placebo · Intervention Types: Drug
CBD (Group 1)
Drug
Experimental Group · 1 Intervention: Cannabis, placebo · Intervention Types: Drug
CBD (Group 2)
Drug
Experimental Group · 1 Intervention: Cannabis, placebo · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline and after ingestion at (60 minutes, 120 minutes, 210 minutes, 300 minutes, 360 minutes)

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
327 Previous Clinical Trials
113,817 Total Patients Enrolled
2 Trials studying Cannabis
880 Patients Enrolled for Cannabis
Didier Jutras-Aswad, MD,MSPrincipal InvestigatorCentre hospitalier de l'Université de Montréal (CHUM)
1 Previous Clinical Trials
80 Total Patients Enrolled
1 Trials studying Cannabis
80 Patients Enrolled for Cannabis

Eligibility Criteria

Age 21 - 65 · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You only used cannabis a few times, and it was within the last 28 days.

Who else is applying?

What state do they live in?
Quebec100.0%
What site did they apply to?
Centre de recherche du Centre Hospitalier Universitaire de Montréal100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%
Why did patients apply to this trial?
  • "i have raging adhd and anxiety."
How many prior treatments have patients received?
1100.0%

Frequently Asked Questions

Is it possible to become a participant in this experiment?

"This medical investigation will include 70 people who are of age between 21 and 65, and have only used cannabis infrequently (3 days or less) in the four weeks prior to enrollment. To be considered for participation, a signed informed consent must be produced by all applicants as well as their agreement to abstain from any non-alcoholic/nicotine drugs during the study period. Furthermore, those with childbearing potential must present a negative pregnancy test at screening and subsequent visits along with a promise not to become pregnant while on trial; they also need to use an accepted contraceptive method throughout the duration of this research. Finally, fluency in either" - Anonymous Online Contributor

Unverified Answer

Is this study actively enrolling participants?

"This study, as displayed on clinicaltrials.gov, is still enrolling participants and was first announced in late July 2022 before undergoing a significant edit towards the end of November that same year." - Anonymous Online Contributor

Unverified Answer

Is the age eligibility for this clinical trial restricted to individuals 50 and over?

"This investigation has imposed an age restriction of between 21 to 65. Conversely, there are 16 separate trials tailored for people who have not reached the legal age and 53 studies designated for those above retirement-age." - Anonymous Online Contributor

Unverified Answer

What is the participant capacity for this research project?

"Affirmative. The clinicaltrials.gov platform attests to the fact that this medical trial, initiated on July 22nd 2022, is in an active recruitment phase. 70 volunteers need to be sourced from a single location for the study's completion." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.